Sugi Predict

Sugi Predict / Compounds / SCHEMBL3815550

SCHEMBL3815550

SCHEMBL3815550

CC(C)(C)NC(=O)OCCNc1nc(NC(=O)C(F)(F)F)ccc1[N+](=O)[O-]

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.38
▸ SIRT5 Q9NXA8 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ FOLH1 Q04609 1/20 0.34
▸ AR P10275 4/20 0.34
▸ PGR P06401 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ PDK1 Q15118 1/20 0.33
▸ PDK2 Q15119 1/20 0.33
▸ PDK3 Q15120 1/20 0.33
▸ PDK4 Q16654 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ ALOX12 P18054 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3816138 0.85 GBA1 (0.34) MAPTSMN1; SMN2CYP3A4ALDH1A1HPGD
SCHEMBL3815554 0.82 LATS1 (0.42) MAPTSIRT5SMN1; SMN2FOLH1ALDH1A1
SCHEMBL3813742 0.82 MAPT (0.57) MAPTSMN1; SMN2LMNACYP3A4HTT
SCHEMBL3812411 0.81 MAPT (0.44) MAPTSIRT5SMN1; SMN2LMNAHTT
SCHEMBL3815680 0.78 MAPT (0.55) MAPTSIRT5SMN1; SMN2LMNAHTT
SCHEMBL3811498 0.74 MAPT (0.38) MAPTSMN1; SMN2LMNAFOLH1CYP3A4
SCHEMBL3815619 0.72 MAPT (0.38) MAPTSIRT5SMN1; SMN2LMNAFOLH1
SCHEMBL13922790 0.72 AR (0.41) SMN1; SMN2LMNAARPGRCYP3A4
SCHEMBL28564189 0.69 HTT (0.44) MAPTSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL11628945 0.67 MAPT (0.57) MAPTSMN1; SMN2LMNAARPGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615925-B1 IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS IPSEN PHARMA (FR) 2009-05-27 — — EP disclosed
US-7495009-B2 Imidazopyridine derivatives as melancortin receptor agonists SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-02-24 — — US disclosed
US-20060173036-A1 Imidazopyridine derivatives as melanocortin receptor agonists SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) 2006-08-03 — — US disclosed
EP-1615925-A1 IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2006-01-18 — — EP disclosed
WO-2004089951-A1 IMIDAZOPYRIDINE DERIVATIVES HAVING AN AFFINITY FOR MELANOCORTIN RECEPTORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-10-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173036-A1 Imidazopyridine derivatives as melanocortin receptor agonists MC4R, MC1R, MC3R MAPT 2117/4885SIRT5 994/4885SMN1; SMN2 3272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.